Page 2,817«..1020..2,8162,8172,8182,819..2,8302,840..»

American Society of Plastic Surgery's Public Safety Campaign is On Target, notes Dr. J

Posted: Published on January 13th, 2015

LOS ANGELES, Jan. 13, 2015 /PRNewswire/ --The American Society of Plastic Surgery has launched a public awareness campaign to encourage prospective patients to thoroughly vet physicians to ensure that they are truly qualified plastic surgeons. Spurred by reports that more customers visiting qualified surgeons are asking them to correct problems related to mishandled procedures, the ASPS campaign is publicly encouraging patients to make sure that physicians are board certified as plastic surgeons before seriously considering them. Noted Beverly Hills Plastic Surgeon Payam Jarrah-Nejad, M.D., F.I.C.S., F.A.C.S., supports the awareness campaign and has long been very vocal about his concerns that too many individuals are obtaining procedures from doctors who are not qualified plastic surgeons. An active member of the ASPS and double board certified by both the American Board of Plastic Surgery and the American Board of Surgery, the doctor known more familiarly to his patients as Dr. J, is one of the most respected physicians working in the highly competitive Beverly Hills and Los Angeles markets. Still, as the holder of numerous plastic surgeons awards, the surgeon is highly aware that vulnerable patients can fall prey to promises of nearly miraculous plastic surgery outcomes for bargain-basement prices. Work done … Continue reading →

Posted in Aesthetic Surgery | Comments Off on American Society of Plastic Surgery's Public Safety Campaign is On Target, notes Dr. J

Stem Cell Therapy: A cure for Diabetes | PlacidWay – Video

Posted: Published on January 13th, 2015

Stem Cell Therapy: A cure for Diabetes | PlacidWay http://tiny.cc/DiabetesCure2015 Diabetes treatment can consist of numerous elements, consisting of standard medications, alternative medication, and natural ... By: Robert Esser … Continue reading →

Comments Off on Stem Cell Therapy: A cure for Diabetes | PlacidWay – Video

Peter S. Kim Named the Virginia and D.K. Ludwig Professor of Biochemistry at Stanford

Posted: Published on January 13th, 2015

Contact Information Available for logged-in reporters only Newswise January 13, 2015 New York, NY Peter S. Kim has been named the Virginia and D.K. Ludwig Professor of Biochemistry at Stanford University School of Medicine. Established in 1994, Ludwig professorships have since been awarded to a total of 15 leading scientists at academic institutions affiliated with the six U.S.-based Ludwig Centers. With this appointment Kim also becomes a member of the Ludwig Center for Cancer Stem Cell Research and Medicine at Stanford. Kims lab focuses on the mechanisms by which viral membranes fuse with cell membranes, which has to happen for the virus to invade its target cell. His team also studies how that process might be disrupted by small molecules and antibodies. Kims lab is, for example, using such studies to engineer antigens for a vaccine that might elicit antibodies that block a key step in HIVs invasion of its target cell. The strategies that he is developing could be applied to design new preventive and therapeutic vaccines for cancers. His lab is also developing methods to identify small molecules that bind tightly and very specifically to proteins that have so far proved resistant to targeting by typical drug-like molecules. … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on Peter S. Kim Named the Virginia and D.K. Ludwig Professor of Biochemistry at Stanford

LLY Collaborates With BMY And MRK, CLTX On Watchlist, ZLTQ Continues To Grow

Posted: Published on January 13th, 2015

Bristol-Myers Squibb Co. (BMY: Quote) has entered into a clinical collaboration agreement with Eli Lilly and Co. (LLY: Quote) to explore combination regimens from its immuno-oncology portfolio with other mechanisms of action that may accelerate the development of new treatment options for patients. As per the agreement terms, a phase 1/2 trial will evaluate Bristol-Myers Squibb's approved immunotherapy Opdivo in combination with Lilly's investigational Galunisertib as a potential treatment option for patients with advanced (metastatic and/or unresectable) glioblastoma, hepatocellular carcinoma and non-small cell lung cancer. Opdivo is approved by FDA for intravenous use for the treatment of patients with unresectable or metastatic melanoma while Galunisertib is currently under investigation as an oral treatment for advanced/metastatic malignancies, including phase 2 evaluation in hepatocellular carcinoma, myelodysplastic syndromes (MDS), glioblastoma, and pancreatic cancer. In other related news, Lilly has also entered into a collaboration agreement with Merck & Co. Inc. (MRK: Quote) to evaluate the safety, tolerability and efficacy of Merck's KEYTRUDA in combination with Lilly compounds in multiple clinical trials. Merck's KEYTRUDA was granted accelerated approval by FDA last September for unresectable or metastatic melanoma with disease progression following Ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. BMY closed Tuesday's … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on LLY Collaborates With BMY And MRK, CLTX On Watchlist, ZLTQ Continues To Grow

First contracting human muscle grown in laboratory

Posted: Published on January 13th, 2015

Researchers at Duke University report the first lab-grown, contracting human muscle, which could revolutionize drug discovery and personalized medicine VIDEO:Duke engineers have engineered the first ever contracting lab-grown human muscles. This video shows forceful contraction of the human muscle bundles in response to electrical stimulation followed by a genetically... view more DURHAM, N.C. -- In a laboratory first, Duke researchers have grown human skeletal muscle that contracts and responds just like native tissue to external stimuli such as electrical pulses, biochemical signals and pharmaceuticals. The lab-grown tissue should soon allow researchers to test new drugs and study diseases in functioning human muscle outside of the human body. The study was led by Nenad Bursac, associate professor of biomedical engineering at Duke University, and Lauran Madden, a postdoctoral researcher in Bursac's laboratory. It appears January 13 in the open-access journal eLife "The beauty of this work is that it can serve as a test bed for clinical trials in a dish," said Bursac. "We are working to test drugs' efficacy and safety without jeopardizing a patient's health and also to reproduce the functional and biochemical signals of diseases -- especially rare ones and those that make taking muscle biopsies difficult." Bursac … Continue reading →

Posted in Stem Cell Human Trials | Comments Off on First contracting human muscle grown in laboratory

Lung Institute to Open New Clinic in Scottsdale in February 2015

Posted: Published on January 13th, 2015

Scottsdale, AZ (PRWEB) January 13, 2015 In February 2015, the Lung Institute will open a new clinic in Scottsdale, AZ. This expansion marks its third location in the country. With stem cell treatment centers already in Tampa and Nashville, the Lung Institute has made positive impacts in the lives of their patients and the surrounding communities. The Lung Institute is committed to providing patients with an effective way to treat pulmonary conditions, rather than just manage their symptoms, which results in an improvement in their overall quality of life. Their application of innovative technology combined with advanced stem cell treatments enables them to carry out their mission and successfully provide world-class care to their patients who visit the Lung Institute from across the globe. Medical Director, Dr. Burton Feinerman, a world-renowned physician and expert in the field of regenerative medicine, has led the Lung Institute in performing hundreds of minimally invasive, outpatient stem cell treatments for a variety of debilitating lung diseases. The Lung Institute treats conditions such as COPD, pulmonary fibrosis, chronic bronchitis, emphysema, and interstitial lung disease. The addition of this treatment center will create jobs in the medical, sales, and administrative industries. Additionally, local businesses, and the … Continue reading →

Comments Off on Lung Institute to Open New Clinic in Scottsdale in February 2015

Curing My Eyelid Eczema

Posted: Published on January 13th, 2015

Winter 2009/2010 was the first time in over half a decade that I was NOT affected (at all) by eyelid / face eczema. To me, this is the some of the best news ever! ((If you have ever had to deal with horrible eczema on your face, you know what I mean)) Follow my journey as I overcame the horrible experience of eyelid / face eczema. Please let me know your thoughts and experiences!! August 15, 2010 Posted by Mariana | Uncategorized | 8 Comments In my constant effort to stay away from all things cat-like, I have successfully maintained a 100% eczema-less face for the better part of the last 6 months. I have found that my immediate reaction to cats has mellowed out a bit, too I no longer flare up if the person next to me in line has cat hair on their coat. I can walk into a house that has cats, as long as I leave within 3-5 minutes and do not touch anything. I figure my body is no longer in crisis mode so it has become a bit more tolerant. Just a bit, though. I still refuse to go to a pet store … Continue reading →

Posted in Eczema | Comments Off on Curing My Eyelid Eczema

Parent Project Muscular Dystrophy Announces New CEO, John Porter, PhD

Posted: Published on January 13th, 2015

HACKENSACK, N.J., Jan. 12, 2015 /PRNewswire-USNewswire/ --Parent Project Muscular Dystrophy (PPMD), a nonprofit organization dedicated to the fight to end Duchenne muscular dystrophy (Duchenne), announced that John Porter, PhD, former program director of the National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke (NINDS) will take on the role of Chief Executive Officer for the organization. For 20 years, PPMD has led the fight to end Duchenne the most common fatal genetic disorder diagnosed in childhood, affecting approximately one in every 3,500 to 5,000 live male births. The loss of a key muscle protein called dystrophin causes muscle wasting and weakness, eventually leading to the loss of ambulation, difficulty breathing, and heart failure. Death typically occurs in the mid-to late 20s. As program director at the NIH/NINDS, Dr. Porter was responsible for managing a portfolio of research grants across neuromuscular disorders and served as Executive Secretary of the interagency Muscular Dystrophy Coordinating Committee. Prior to that, he served as Professor of Neurology at Case Western Reserve University, where he was supported by the NIH and advocacy groups for research on muscle biology in health and disease, including muscle group responses to Duchenne. "PPMD is beyond thrilled to have … Continue reading →

Posted in Muscular Dystrophy Treatment | Comments Off on Parent Project Muscular Dystrophy Announces New CEO, John Porter, PhD

Sarepta Therapeutics (SRPT) Stock Hits One-Year Low Today After Eteplirsen Update

Posted: Published on January 13th, 2015

NEW YORK (TheStreet) -- Shares ofSarepta Therapeutics (SRPT) plunged more than 18% to a 52-week low of $11.33 on Monday after the biopharmaceutical company provided a 168-week update on its study of eteplirsen, the company's Duchenne muscular dystrophy (DMD) treatment. Sarepta's update revealed thatanaccelerated decline in walking ability in the 168th week compared to the previous update after week 144. All the DMD patients lost some walking ability in the trial. However, the update also revealed some encouraging news, as patients in the trialcontinue to walk more than three years after starting eteplirsen treatment. The patients showed no significant side effects or tolerability problems. Eteplirsen also seemed to slow the progression of DMD in the patients. Must Read:Sarepta Updates Eteplirsen Study Results, FDA Filing Still on for Mid Year Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade. Access the tool that DOMINATES the Russell 2000 and the S&P 500. Jim Cramer's protg, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar. Read the original here: Sarepta Therapeutics (SRPT) Stock Hits One-Year Low Today After Eteplirsen Update … Continue reading →

Posted in Muscular Dystrophy Treatment | Comments Off on Sarepta Therapeutics (SRPT) Stock Hits One-Year Low Today After Eteplirsen Update

Ballarat autism blogger threatened with death

Posted: Published on January 13th, 2015

Jan. 13, 2015, 5 p.m. Ballarat man Philip Gluyas claims to be living in fear after anti-autism blogger Oliver Canby. Philip Gluyas. PICTURE: THE COURIER Two "keyboard warriors" - one in Victoria and one in Los Angeles -were involved in heated online arguments over the existence of autism that quickly escalated into death threats, a court has heard. Philip Gluyas, 49, an umpire in the Ballarat junior football leaguewith Asperger's syndrome, claims to be living in fear afteranti-autism blogger Oliver Canby urged people to kill him in a seriesof posts on the website 'Autism is Bad'. Canby, who lives in Los Angeles, wanted people to show up at MrGluyas' Sebastopol home and murder him, the Supreme Court was told onTuesday. Canby, who does not believe Asperger's exists, claimed he would offera $500 reward to anyone who carried out the murder. Mr Gluyas, an outspoken advocate for the rights of people with autism,is suing Canby in the Victorian Supreme Court for defamation claiminghe had made false and malicious statements about him, exposing him tohate, ridicule and contempt. Mr Gluyas, who runs the blog 'Phil Gluyas: Autism News and Views. Thetruth about Autism is here', was first diagnosed with Asperger's in1997. The … Continue reading →

Comments Off on Ballarat autism blogger threatened with death

Page 2,817«..1020..2,8162,8172,8182,819..2,8302,840..»